Last reviewed · How we verify
STASIS
STASIS, developed by Baqiyatallah Medical Sciences University, is a marketed small molecule with an undisclosed mechanism of action, currently holding an unspecified market position. The key strength of STASIS lies in its key composition patent, which is set to expire in 2028, providing a period of exclusivity. The primary risk is the unknown mechanism of action, which may limit its differentiation and acceptance in the market.
At a glance
| Generic name | STASIS |
|---|---|
| Sponsor | Baqiyatallah Medical Sciences University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Achilles Tendinopathy Embolization (PHASE1)
- Affordable Made-in-India Microspheres for Liver Cancer Therapy (PHASE1)
- Lateral Plantar Artery Embolization For Plantar Fasciitis (PHASE1)
- Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy (PHASE3)
- A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications (NA)
- Weak Pulse at Yang and Wiry Pulse at Yin Theory (NA)
- Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture (NA)
- Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STASIS CI brief — competitive landscape report
- STASIS updates RSS · CI watch RSS
- Baqiyatallah Medical Sciences University portfolio CI